CPBTD
NBIX icon

Central Pacific Bank - Trust Division’s Neurocrine Biosciences NBIX Stock Holding History

Central Pacific Bank - Trust Division’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$238K Hold
1,675
– – 0.03% 417
2026
Q2 		$282K Hold
1,675
– – 0.03% 412
2026
Q1 		$221K Sell
1,675
-50
-3% -$6.63K 0.03% 436
2025
Q4 		$245K Hold
1,725
– – 0.03% 404
2025
Q3 		$242K Hold
1,725
– – 0.03% 410
2025
Q2 		$217K Buy
1,725
+100
+6% +$11.5K 0.03% 426
2025
Q1 		$180K Sell
1,625
-2,077
-56% -$263K 0.02% 463
2024
Q4 		$505K Sell
3,702
-1,200
-24% -$148K 0.07% 262
2024
Q3 		$565K Sell
4,902
-2,335
-32% -$320K 0.07% 261
2024
Q2 		$996K Buy
7,237
+937
+15% +$128K 0.12% 181
2024
Q1 		$891K Buy
+6,300
New +$860K 0.11% 208

Other funds holding NBIX

CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
ACM
Argent Capital Management St Louis, Missouri $3.14B AUM 31.36% 1-Year Est. Return
RSC
Red Spruce Capital Berwyn, Pennsylvania $283M AUM 29.49% 1-Year Est. Return
MNBTD
Moody National Bank Trust Division Galveston, Texas $1.21B AUM 28.25% 1-Year Est. Return
JWS
Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
WWM
Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
PCS
Private Client Services Louisville, Kentucky $372M AUM 17.65% 1-Year Est. Return
CCAL
City Center Advisors LLC Troy, Michigan $131M AUM 24.02% 1-Year Est. Return

Central Pacific Bank - Trust Division's NBIX Position: Q3 2026 in Review

Central Pacific Bank - Trust Division held its Neurocrine Biosciences (NBIX) position steady in Q3 2026 at 1,675 shares worth $238K. The position accounts for 0.03% of the portfolio, ranked #417.

Central Pacific Bank - Trust Division first reported a position in NBIX in Q1 2024 and has held it in 11 quarters since. The position peaked at $996K in Q2 2024. 21 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Central Pacific Bank - Trust Division held 1,675 shares of Neurocrine Biosciences worth $238K as of Q3 2026.
  • Central Pacific Bank - Trust Division left its Neurocrine Biosciences share count unchanged in Q3 2026.
  • Neurocrine Biosciences made up 0.03% of Central Pacific Bank - Trust Division's portfolio in Q3 2026, its #417 holding.
  • Central Pacific Bank - Trust Division first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 11 quarters since.
  • Central Pacific Bank - Trust Division's Neurocrine Biosciences position peaked at $996K in Q2 2024.
  • 21 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Central Pacific Bank - Trust Division's 13F filing for Q3 2026, filed 6 Oct 2026.